View Author
patient response fatigue imatinib treatment month cytarabine study disease relapse therapy cytogenetic response myeloid leukemia blood cytogenetic cycle level combination score leukemia combination therapy /medium fatigue vs allogeneic phase survival transplantation netherland cell transplantation group myeloid result hematologic follow-up lenalidomide analysis grade center fatigue vs toxicity progression table hrqol trial autologou assessment allogeneic nma sct myeloma response rate signi hematologic response /medium figure crohn bcr-abl scale fi rst cycle incidence university number erasmus mc 1 year maintenance autologous sct blast crisis range criteria protocol allo-sct 800 mg recovery department value symptom allogeneic sct intermediate-dose cytarabine effect hodgkin quality marrow -20
7 Most Recent Publications
|
High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group
(Article)
Thielen, N. Holt, B. van der Schipperus, M.R. Schattenberg, A.V.M.B. Marwijk Kooy, R. van Smit, W.M. Chu, I.W.T. Valk, P.J.M. Ossenkoppele, G.J. Cornelissen, J.J. Verhoef, G.E.G. Ammerlaan, R.A.H.M. Sonneveld, P. Janssen, J.J.W.M. Deenik, W. Falkenburg, J.H.F. Kersten, M.J. Sinnige, H. |
2013-04-10
|
|
Long-term follow-up of autologous hematopoietic stem cell transplantation for severe refractory Crohn's disease
(Article)
Hommes, D.W. Duijvestein, M. Zelinkova, Z. Stokkers, P.C.F. Ley, M.H.D. Stoker, J. Voermans, C. Oers, M.H.J. van Kersten, M.J. |
2011-12-01
|
|
Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: Results of the HOVON 76 Trial
(Article)
Kneppers, E. Holt, B. van der Bruijnen, C.P. Emmelot, M. Sonneveld, P. Lokhorst, H.M. Mutis, T. Minnema, M.C. Kersten, M.J. Zweegman, S. Meijer, E. Huls, G. Cornelissen, J.J. Janssen, J.J. Huisman, C. Cornelisse, P.B. |
2011-09-01
|
|
Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia
(Article)
Deenik, W. Janssen, J.J.W.M. Sonneveld, P. Marwijk Kooy, M. van Wittebol, S. Willemze, R. Wijermans, P.W. Beverloo, H.B. Löwenberg, B. Valk, P.J.M. Ossenkoppele, G.J. Cornelissen, J.J. Holt, B. van der Verhoef, G.E.G. Smit, W.M. Kersten, M.J. Daenen, S.M.G.J. Verdonck, L.F. Ferrant, A. Schattenberg, A.V.M.B. |
2010-06-01
|
|
Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial
(Article)
Heutte, N. Flechtner, H.H. Thomas, J. Lugtenburg, P.J. Viterbo, L. Carde, P. Hagenbeek, A. Maazen, R.W. van der Smit, W.G. Brice, P. Marwijk Kooy, M. van Baars, J.W. Mounier, N. Poortmans, P. Tirelli, U. Leeksma, O.C. Tomšič, R. Feugier, P. Salles, G. Gabarre, J. Kersten, M.J. Neste, E. van den Creemers, G.J.M. Mellink, W.A. Gaillard, I. Meijnders, P. Tertian, G. Reman, O. Muller, H.P. Troncy, J. Blanc, M. Schroyens, W. Voogt, P.J. Wijermans, P. Meerwaldt, J.H. Rieux, C. Fermé, C. Henry-Amar, M. Eghbali, H. Veer, M.B. van 't Noordijk, E.M. Kluin-Nelemans, J.C. Lampka, E. |
2009-12-01
|
|
Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome
(Article)
Minnema, M.C. Donk, N.W.C.J. van de Zweegman, S. Hegenbart, U. Schonland, S. Raymakers, R. Zijlmans, J.M. Kersten, M.J. Bos, G.M. Lokhorst, H.M. |
2008-05-01
|
|
Dose-finding study of imatinib in combination with intravenous cytarabine: Feasibility in newly diagnosed patients with chronic myeloid leukemia
(Article)
Deenik, W. Holt, B.D. van Sonneveld, P. Kooy, M.M. van Wittebol, S. Willemze, R. Wijermans, P.W. Westveer, P.H.M. Beverloo, H.B. Valk, P.J.M. Löwenberg, B. Ossenkoppele, G.J. Verhoef, G.E.G. Cornelissen, J.J. Smit, W.M. Kersten, M.J. Kluin-Nelemans, H.C. Verdonck, L.F. Ferrant, A. Schattenberg, A.V.M.B. Janssen, J.J.W.M. |
2008-03-01
|
